Ignite Creation Date:
2024-05-06 @ 8:19 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06332430
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-03-27
First Post:
2024-03-20
Brief Title:
Intratumoral CAN2109 in Subjects With Solid Tumors or Lymphomas
Sponsor:
Canwell Biotech Limited
Organization:
Canwell Biotech Limited
Study Overview
Official Title:
A Phase 1 Dose Escalation Open-Label Study of Intratumoral CAN2109 in Subjects With Unresectable or Metastatic Advanced Solid Tumors or Lymphomas
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A phase 1 dose escalation open-label study of intratumoral CAN2109 in subjects with unstable or metastatic advanced solid tumors or lymphomas
Detailed Description:
The scope of the study is to evaluate the safety of CAN2109 in humans explore its safety efficacy and collect data on the pharmacokinetics as well as on the pharmacodynamic effect of the drug on the immune system locally and systemically and on tumor markers
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None